PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer
Abstract PARP inhibitors were recently approved for treatment of molecularly-defined subsets of metastatic castrate-resistant prostate cancer (mCRPC) patients. Although the PARP inhibitor olaparib was approved for use in patients with a mutation in one of fourteen genes, the mutation frequency of th...
Salvato in:
| Autori principali: | , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Nature Portfolio
2022-06-01
|
| Serie: | npj Precision Oncology |
| Accesso online: | https://doi.org/10.1038/s41698-022-00291-7 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|